Results 111 to 120 of about 85,599,609 (253)

Alogliptin: a new addition to the class of DPP-4 inhibitors

, 2009
Radha Andukuri, Andjela Drincic, Marc RendellDivision of Endocrinology, Department of Medicine, Creighton University School of Medicine, Omaha, Nebraska, USABackground: Alogliptin is an oral antihyperglycemic agent that is a selective inhibitor of the ...
Radha Andukuri, Andjela Drincic, Marc Rendell   +2 more
core  

Anti‐obesity medications and incident ocular outcomes: A systematic review and network meta‐analysis

VIEW, EarlyView.
In this systematic review and network meta‑analysis of 140 studies, anti‑obesity medications showed heterogeneous ocular safety profiles. Semaglutide was associated with higher NAION risk (observational data), whereas dual/multi‑agonists and glucagon‐like peptide‐1 receptor agonists demonstrated favourable glaucoma and overall ocular outcomes ...
Linge Jian, Keke Zhang, Wenwen He, Yan Ke, Yi Lu, Xiangjia Zhu   +5 more
wiley   +1 more source

Glucagon‐Like Peptide‐1 Receptor Agonists in Pregnancy: Periconception Exposure and Perinatal Outcomes

BJOG: An International Journal of Obstetrics &Gynaecology, EarlyView.
ABSTRACT Objective An increasing number of women of childbearing age worldwide are using glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) and are advised to use effective contraception during treatment. Nevertheless, maternity services are encountering increasing numbers of women exposed to GLP‐1 RAs shortly before conception or during pregnancy ...
Katherine G. Y. Lau, Anisha Chopra, Edward Mullins, Rochan Agha‐Jaffar, Tricia Tan, Lynne Sykes, Christina K. H. Yu   +6 more
wiley   +1 more source

A Scalable Synthesis of an Azabicyclooctanyl Derivative, a Novel DPP-4 Inhibitor

, 2016
A practical synthetic strategy to a chiral azabicycclooctanyl derivative (1), a potent DPP-4 inhibitor, starting from a commercially available nortropine is described.
Chuanqin Liu (2407684), Yudong Cao (2407681), Quanbing Wu (2407687), Joe McKenna (2407678), Kenji Namoto (2407693), Zhongbo Fei (2407675), Song Xue (316115), Wen-Chung Shieh (2369281), Kapa Prasad (2062723), Daniel Baeschlin (2407690), Fei Zhang (85787), Mahavir Prashad (1601647)   +11 more
core   +1 more source

Male Sexual and Reproductive Health in Diabetes and Obesity Pharmacotherapy: A Source‐Triangulated Counseling Map

Andrology, EarlyView.
ABSTRACT Background Drugs used for diabetes and obesity increasingly shape male sexual and reproductive counseling, but clinical studies, trial registrations, regulatory labels, and patents answer different questions. Objectives The objective is to map these sources and define what each can support when counseling men receiving metabolic drugs ...
Marek Broul, Michal Dubský, Aneta Hujová, Michaela Liegertová   +3 more
wiley   +1 more source

Surface Energy Modification of Semi-Random P3HTT-DPP

, 2016
Alkyl solubilizing side chains on conjugated polymers can serve as a handle for modifying polymer properties. Recently, oligo-ether and semifluoro alkyl side chains were utilized to tune the surface energy of random P3HT-based polymers without changing ...
Sangtaik Noh (1565080), Seyma Ekiz (2901596), Jenna B. Howard (1565083), Barry C. Thompson (1565077)   +3 more
core   +1 more source

The Impact of Common Medications on Male Fertility: An Updated Systematic Review

Andrology, EarlyView.
ABSTRACT Background Compared with those of cytotoxic treatments, the potential effects of common medications on the fertility of men trying to conceive currently or planning to conceive in the future are less well described. The use of common medications may modify the gonadotropic axis, spermatogenesis, and epididymal maturation or alter male ...
Lina Jebli, Salomé Gallissian, Roxanne Barèges, Félicia Fournier, Catherine Metzler‐Guillemain, Ségolène Prades, Fanny Magnan‐Sebag, Jeanne Perrin   +7 more
wiley   +1 more source

Risk of hyperkalaemia in patients with type 2 diabetes mellitus prescribed with SGLT2 versus DPP-4 inhibitors [PDF]

To investigate the risk of hyperkalaemia in new users of sodium–glucose cotransporter 2 (SGLT2) inhibitors vs. dipeptidyl peptidase-4 (DPP-4) inhibitors among patients with type 2 diabetes mellitus (T2DM).
Tsang, Christopher Tze Wei, Chan, Yap Hang, Cheang, Iok Fai, Tse, Yi Kei, Wu, Mei Zhen, Tse, Hung Fat, Xu, Xin, Lam, Carolyn S.P., Li, Xin Li, Huang, Jia Yi, Teng, Tiew Hwa Katherine, Lee, Chi Ho, Yiu, Kai Hang, Ren, Qing Wen   +13 more
core   +1 more source

Timing and duration of glucagon‐like peptide‐1 receptor agonist use and risk of nonarteritic anterior ischaemic optic neuropathy

Acta Ophthalmologica, EarlyView.
Abstract Purpose To investigate the association between glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) use and nonarteritic anterior ischaemic optic neuropathy (NAION) in type 2 diabetes, examining treatment recency and cumulative duration. Methods This nationwide registry‐based nested case–control study utilizedz Danish health registries (1996 ...
Siar Niazi, Filip Gnesin, Baker Nawfal Jawad, Zia Niazi, Puriya Daniel Wuertz Yazdanfard, Anne P. Toft‐Petersen, Kathrine Kold Sørensen, Amani Meaidi, Yousif Subhi, Christian Torp‐Pedersen   +9 more
wiley   +1 more source

Gut microbiota as a novel therapeutic target for eating disorders and obesity

British Journal of Pharmacology, EarlyView.
The graphical abstract highlights the bidirectional interaction between the gut microbiota and central homeostatic and hedonic mechanisms regulating food intake, which contributes to overweight and obesity. It also illustrates emerging microbiota‐based biomarkers and therapeutic strategies (including prebiotics, probiotics, postbiotics, synbiotics and ...
Solveiga Samulėnaitė, Victor Mathis, Emmanuel Darcq, Aurelijus Burokas, Elena Martín‐García, Rafael Maldonado   +5 more
wiley   +1 more source